Diane Seimetz
Munich, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape.
Journal: Biomarker insights
Published: October 11, 2020
19th Annual Meeting of the Safety Pharmacology Society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products).
Journal: Expert opinion on drug safety
Published: March 13, 2020
From fiction to science: clinical potentials and regulatory considerations of gene editing.
Journal: Clinical and translational medicine
Published: August 07, 2019
Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?
Journal: Cell medicine
Published: October 11, 2018
Advanced therapies in wound management: cell and tissue based therapies, physical and bio-physical therapies smart and IT based technologies.
Journal: Journal of wound care
Published: June 15, 2018
Expediting Drug Development: FDA's New Regenerative Medicine Advanced Therapy Designation.
Journal: Therapeutic innovation & regulatory science
Published: June 14, 2018
The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites patients: results from a phase II/III study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 10, 2014
The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting.
Journal: Human vaccines & immunotherapeutics
Published: August 20, 2013
Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: May 04, 2012
Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: December 01, 2011
Showing 1-10 of 10
Last Updated: 09/26/2026